BIRC3 and breast carcinoma: For cIAP-2 mRNA expression, <8 fold and >8 fold groups were formed, and it was observed that the median survival of breast cancer patients with <8-fold cIAP-2 mRNA expression showed 35 months of overall median survival time, while >8-fold cIAP-2 mRNA expression had 27.90 months of overall median survival, and the difference among both groups was found to be statistically significant (p < 0.0001).